Naked Brand Group Limited (NASDAQ:NAKD)
Naked Brand Group, Inc. designs, manufactures and sells innerwear, lounge apparel and sleepwear products to consumers and retailers. The company’s brand name consists of Naked. It operates primarily in the United States and Canada. Naked Brand Group Inc. is headquartered in New York.
Naked Brand Group Limited (NASDAQ:NAKD)’s Financial Overview
Naked Brand Group Limited (NASDAQ) declined -4.17% yesterday to close its trading session at $0.46. Naked Brand Group Limited has 52-Week high of $11.36 and 52-Week Low of $0.4. The stock touched its 52-Week High on 11.36 and 52-Week Low on 0.40. The stock traded with the volume of 501597 shares yesterday. The firm shows the market capitalization of $22.56 Million.
The firm is trading with SMA20 of -42.35 Percent, SMA50 of -48.97 Percent and SMA200 of -82.14 percent. Naked Brand Group Limited has P/S value of 0.26 while its P/B value stands at 0.87. Similarly, the company has Return on Assets of 0 percent, Return on Equity of 0 percent and Return on Investment of -81 Percent. The company shows Gross Margin and Operating Margin of 32.7 percent and 0 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
There is no forecast data available.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)
Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)’s Financial Outlook
The 3 analysts offering 12-month price forecasts for Catabasis Pharmaceuticals Inc have a median target of 28.00, with a high estimate of 77.00 and a low estimate of 15.00. The median estimate represents a +529.21% increase from the last price of 4.45.
Catabasis Pharmaceuticals, Inc. is estimated to report earnings on 03/21/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.95. The reported EPS for the same quarter last year was $-2.4.
According to Zacks Investment Research, Catabasis Pharmaceuticals, Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock declined -0.22% and closed its last trading session at $4.45. The company has the market capitalization of $32.75 Million. The stock has 52-week high of $23.8 and 52-Week low of $0.39. The firm touched its 52-Week high on 23.80 and 52-Week low on 3.60. The company has volume of 215870 shares. The company has a total of 7.36 Million shares outstanding.
Catabasis Pharmaceuticals, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.8/share where the analyst estimated EPS was $-1.35/share. The difference between the actual and Estimated EPS is $0.55. This shows a surprise factor of 40.7 percent.
The company has YTD performance of 1.83 percent. Beta for Catabasis Pharmaceuticals, Inc. stands at 1.73 while its ATR (average true range) is 0.46. The company has Weekly Volatility of 5.62%% and Monthly Volatility of 7.31%%.
Catabasis Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of -22.89%, Distance from 50-Day Simple Moving Average of -19.28 percent and Distance from 200-Day Simple Moving Average of -47.43%.
The Company currently has ROA (Return on Assets) of -76.8 percent, Return on Equity (ROE) of -91.2 Percent and Return on Investment (ROI) of -189.5% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.